Flagship Pioneering has announced the formation of Etcelera, a company created by the merger of the platforms of Cellarity, Etiome and Empress Therapeutics. The new company aims to pioneer causal intelligence in human biology: the ability to determine what truly drives disease and predict how a medicine… Read More
Australian radiopharmaceuticals spinout, Skopos Bio, has launched with an AUD$12 million (US$8.3 million) seed round, led by a global investor syndicate. The company was founded by three clinical and translational scientists from Melbourne’s Peter MacCallum Cancer Centre (Peter Mac), who continue to treat patients and lead research:… Read More
Seventeen new companies will now benefit from BioInnovation Institute (BII)’s innovation platform, which helps companies attract capital and bring promising technologies to market. The innovation house is providing a total of around €9.5 million. Following the announcement of a new €736 million from the Novo Nordisk Foundation to the BII,… Read More
Palomar Labs (formerly Negev Labs), a venture studio that builds companies around neuropsychiatric drug development programmes with prior human validation, has announced the spinout of Ariadne Bio, its first portfolio company. Ariadne Bio launches with lead programme AB-300, a clinical-stage-ready, non-hallucinogenic serotonin 2A receptor agonist in development… Read More
A new company founded by Deep Science Ventures veterans has closed a £1.5 million (~$2m) pre-seed round and secured £700,000 (~$950K) Innovate UK funding. Big Picture Bio has been founded to identify, design and optimise promising cancer combination therapies, using a generative world model to understand how… Read More
Boulevard Bio has emerged from stealth with $65 million from founding investor Deerfield Management and early Phase I healthy volunteer data for lead candidate BLVD101. Founded by pioneers in B cell biology and incubated by Deerfield Management within Deerfield Discovery and Development (3DC), Boulevard’s approach is grounded… Read More
Lu Rahman shares some of the stand-put momenta at this year’s LSX World Congress in Lisbon. LSX World Congress Europe has always… Read More
Biotechnology company Immutrin has raised £65 ($86.7) million in Series A financing to help fund its lead asset through clinical proof of concept. Immutrin’s lead asset is targeting ATTR cardiomyopathy, a serious and potentially fatal form of amyloidosis. Amyloidosis is a group of rare,… Read More
SLAS, the Society of Laboratory Automation and Screening, has introduced the 12 companies selected for the Innovation AveNEW programme at SLAS Europe 2026 Conference and Exhibition, taking place 19-21 May in Vienna, Austria. Innovation AveNEW provides a platform for participants to showcase their new company, product or… Read More
Atrium Therapeutics has launched as a newly independent, publicly traded company developing RNA therapeutics for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences’ acquisition by Novartis. The company is led by Kathleen Gallagher, President and Chief Executive Officer (CEO),… Read More
Two European biotech venture funds have raised over €1.1 billion in capital in the last week. Sofinnova Partners announced the close of Sofinnova Capital XI at €650 million, while Medicxi closed its Medicxi V fund at €500 million. Sofinnova Capital XI attracted strong support from… Read More
Biopharmaceutical company Crystalys Therapeutics has launched with a $205 million Series A financing round, aiming to address the significant unmet medical needs of people living with gout. The financing round was co-led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of… Read More
Pioneer Group, a specialist in life science infrastructure and venture building, has again teamed up with biopharmaceutical company AbbVie to launch a Golden Ticket programme designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology. Read More
New research into the UK life sciences landscape has revealed a growing trend of investment into more mature companies. Pioneer Group’s ‘Life Science Start Up Report’ also highlights a persistent regional imbalance, with ‘Golden Triangle’ university spinouts attracting significantly more funding than… Read More
Dispatch Bio has officially launched with a stated mission to engineer a universal treatment across solid tumours. Immunotherapies have struggled to effectively treat solid tumours due to the lack of a tumour-specific target and the presence of an immune-suppressive tumour microenvironment. Dispatch’s Flare platform has… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody… Read More
